Drug Profile


Alternative Names: PPL-1

Latest Information Update: 25 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pitney Pharmaceuticals
  • Developer PharmAust
  • Class Acetonitriles; Anthelmintics; Antineoplastics
  • Mechanism of Action Cyclin-dependent kinase 2 modulators; Cyclin-dependent kinase 4 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 01 Aug 2016 Phase-I/II development is ongoing in Australia
  • 17 Jun 2014 Phase-I/II clinical trials in Solid tumours (refractory metastatic disease, second-line therapy or greater) in Australia (PO)
  • 25 Jul 2013 Pitney Pharmaceuticals and an undisclosed company agree to co-develop monepantel in Australia for cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top